Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program

Université Laval

$25,833.00

The interleukin-1 system as a potential target for treatment of endometriosis: study of its involvement in endometriosis-associated abnormal growth and development in vitro and in vivo.

EF 2009-10

Résumé
Our previous studies revealed that intra-uterine endometrial cells of women with endometriosis, a frequent gynecological disease thought to arise from the ectopic growth of endometrial tissue, are highly responsive to the major multifunctional and pro-inflammatory cytokine interleukin-1 (IL1). We further found a marked deficiency in IL1 receptor type 2 (IL1R2, the decoy inhibitory IL1 receptor), in the eutopic endometrium of endometriosis patients and an imbalance in IL1R1 (the signaling activating receptor) and IL1R2 expression in ectopic and eutopic endometrial tissues. In view of IL1 well-documented role in the pathophysiology of endometriosis and cell survival, the objectives of the present research proposal are to delineate the role of IL1R2 deficiency in the capability of endometrial cells to proliferate and favor their own growth and development into ectopic host tissues using in vitro and in vivo models. This study may have a considerable interest 1) for a better understanding of the mechanisms underlying the pathogenesis of endometriosis and the delineation of the molecular targets of IL-1-mediated abnormal endometrial cell growth and responsiveness, and 2) for potential targeted treatment of endometriosis using soluble rhsIL1R2.
Programme
Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
194596
Name
Khoufache KHALED
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Wyeth Pharmaceuticals
Instname2
Human Development, Child and Youth Health
Theme2
Clinical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
The interleukin-1 system as a potential target for treatment of endometriosis: study of its involvement in endometriosis-associated abnormal growth and development in vitro and in vivo.
Programtype2
Fellowship Programs
Orgnameinp2
Université Laval
Cihramount2
$25,833
Cihrequipment2
$0
Programname2
Fellowship - CIHR/Rx&D - Wyeth Pharmaceuticals Research Program
Keyworddelim
Angiogenesis; Appoptosis; Endometriosis; Human Endometrium; Il-1; In Vivo Study; Nude Mice; Treatment.
Abstract
Our previous studies revealed that intra-uterine endometrial cells of women with endometriosis, a frequent gynecological disease thought to arise from the ectopic growth of endometrial tissue, are highly responsive to the major multifunctional and pro-inflammatory cytokine interleukin-1 (IL1). We further found a marked deficiency in IL1 receptor type 2 (IL1R2, the decoy inhibitory IL1 receptor), in the eutopic endometrium of endometriosis patients and an imbalance in IL1R1 (the signaling activating receptor) and IL1R2 expression in ectopic and eutopic endometrial tissues. In view of IL1 well-documented role in the pathophysiology of endometriosis and cell survival, the objectives of the present research proposal are to delineate the role of IL1R2 deficiency in the capability of endometrial cells to proliferate and favor their own growth and development into ectopic host tissues using in vitro and in vivo models. This study may have a considerable interest 1) for a better understanding of the mechanisms underlying the pathogenesis of endometriosis and the delineation of the molecular targets of IL-1-mediated abnormal endometrial cell growth and responsiveness, and 2) for potential targeted treatment of endometriosis using soluble rhsIL1R2.
Competitiondate
200910
Approvedterm2
1 yr 2 mths
Pinamesdelim
Khoufache, KHALED
Approvedterm
1 an 2 mois
Cihrcontribution2
~ $25,833~ $0~